Silence Therapeutics has reported its siRNA drug candidate showed positive results in a mid-stage test of patients with high low-density lipoprotein at risk of cardiovascular events, hitting benchmarks set by some analysts.
The UK biotech also reported Wednesday that Mallinckrodt decided to stop further development of complement C3-targeting drug SLN501…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
